<DOC>
	<DOCNO>NCT00760838</DOCNO>
	<brief_summary>The purpose study evaluate efficacy , safety cost-effectiveness azithromycin add-on therapy adult subject severe persistent asthma , remain inadequately control despite GINA ( 2006 ) step 4 5 therapy .</brief_summary>
	<brief_title>AZISAST Study : AZIthromycin Severe ASThma Study</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Azithromycin</mesh_term>
	<criteria>1. patient give write informed consent 2. male female race 3 . 1875 year age 4. diagnosis persistent asthma ≥ 1 year duration screen history consistent GINA step 4 5 clinical feature 5. receive high dose ICS plus inhaled LABA least 6 month prior screen 6. patient suffered multiple ( i.e . least two ) independent document severe asthma exacerbation within previous 12 month 7. patient must neversmokers exsmokers smoke history ≤ 10 packyears . 1. female pregnant breastfeed 2. patient severe bronchiectasis 3. patient active tuberculosis nontuberculous mycobacterial infection ( NTM ) 4. patient significant underlying medical condition ( e.g . infection , hematological disease , malignancy , neurologic , renal , hepatic , coronary heart disease cardiovascular disease , endocrinologic gastrointestinal disease ) within previous 3 month 5. unable perform spirometry complete patient diary complete questionnaire 6. patient know hypersensitivity azithromycin macrolide antibiotic 7. patient 's heart rate correct QT interval prolong 8. patient judgement investigator clinically relevant laboratory abnormality 9. patient currently treat macrolide antibiotic recent macrolide treatment ( past twelve week ) 10. antiIgE treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Inadequately control severe asthma</keyword>
</DOC>